BRIDGEBIO PHARMA INC (BBIO) Stock Analyst Ratings
USA - NASDAQ:BBIO - US10806X1028 - Common Stock
62.73 USD
-0.64 (-1.01%)
ChartMill assigns a Buy % Consensus number of 85% to BBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 71.13. This target is 13.39% above the current price.
BBIO was analyzed by 24 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about BBIO.
In the previous month the buy percentage consensus was at a similar level.
BBIO was analyzed by 24 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-30 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-30 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-30 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-21 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-12 | UBS | Maintains | Buy -> Buy |
| 2025-09-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-08-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-29 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-07-21 | Truist Securities | Initiate | Buy |
| 2025-07-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-14 | Jefferies | Initiate | Buy |
| 2025-07-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-06-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-06-25 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-17 | Wolfe Research | Initiate | Outperform |
| 2025-06-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-30 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-04-30 | UBS | Maintains | Buy -> Buy |
| 2025-04-30 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-31 | Redburn Atlantic | Initiate | Buy |
BRIDGEBIO PHARMA INC / BBIO FAQ
Can you provide the average price target for BRIDGEBIO PHARMA INC stock?
24 analysts have analysed BBIO and the average price target is 71.13 USD. This implies a price increase of 13.39% is expected in the next year compared to the current price of 62.73.
What is the consensus rating for BRIDGEBIO PHARMA INC (BBIO) stock?
The consensus rating for BRIDGEBIO PHARMA INC (BBIO) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for BBIO stock?
The number of analysts covering BRIDGEBIO PHARMA INC (BBIO) is 24.